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Tumor necrosis factor-a (TNFa) has been shown to
play an important role in the pathogenesis of silicotic
fibrosis. In this study, antisense oligonucleotides tar-
geted to TNFa mRNAwere used to inhibit silica-induced
TNFa gene expression in alveolar macrophages. To
achieve macrophage-specific oligonucleotide delivery, a
molecular conjugate consisting of mannosylated polyly-
sine that exploits endocytosis via the macrophage
mannose receptor was used. Complexes were formed
between the mannosylated polylysine and oligonucleo-
tides and added to the cells in the presence of silica.
Enzyme-linked immunoadsorbent assay showed that
the complex consisting of the conjugate and antisense
oligomer effectively inhibited TNFa production,
whereas the oligomer alone had much less effect. Re-
verse transcriptase-polymerase chain reaction analysis
revealed that the reduction in TNFa secretion was asso-
ciated with specific ablation of targeted TNFa mRNA.
The conjugate alone or conjugate complexed with in-
verted or sense sequence oligonucleotide had no effect.
The promoting effect of the conjugate on antisense ac-
tivity was shown to be due to enhanced cellular uptake
of the oligomer via mannose receptor-mediated endocy-
tosis. Cells lacking mannose receptors showed no sus-
ceptibility to the conjugate treatment. These results in-
dicate that effective and selective inhibition of
macrophage TNFa expression can be achieved using the
antisense mannosylated polylysine system.
Tumor necrosis factor-a (TNFa)1 is a macrophage-derived
peptide that has been shown to play an important role in the
pathogenesis of pulmonary fibrosis (1–3). Several fibrogenic
agents such as crystalline silica and asbestos stimulate TNFa
mRNA expression and protein synthesis in macrophages (2, 3).
Elevated TNFa levels stimulate fibroblast proliferation and
production of collagen matrix, leading to fibrosis (2–4). Al-
though the role of TNFa in the pathogenesis of pulmonary
fibrosis has been well studied, relatively little is known about
its molecular regulation during the fibrotic process. This infor-
mation is important not only for the understanding of the
molecular mechanism of disease pathogenesis but also for the
development of potential therapeutic interventions.
The ability to regulate expression of an individual gene by
the use of an antisense oligonucleotide (ON) complementary to
a specific sequence of mRNA provides a powerful tool for elu-
cidating the role of a particular gene and may allow therapeutic
intervention when that gene is overexpressed (5). The strong
binding affinity of ONs to their mRNA targets makes these
compounds potent and specific inhibitors of gene expression (6).
To take advantage of this specificity, however, the ONs must
also be delivered selectively to the intended target cells, where
they can find and bind to their target mRNA sequences. The
lung represents a major target for antisense therapy for dis-
eases such as cancer and fibrosis. However, the complex anat-
omy of the lung as well as the presence of numerous lung cell
types make ON targeting in this organ difficult. Furthermore,
ONs are structurally bulky and highly charged, so their cellu-
lar uptake is generally low (7) and must be enhanced.
Receptor-mediated endocytosis offers the potential to target
a selected cell population and enhance cellular uptake of ONs.
This method has been used successfully to aid ON delivery in
selected cell types (8–11). For example, asialoorosomucoid-
polylysine conjugates have been used to target ONs to HepG2
and chloramphenicol acetyltransferase cells (8, 9), and trans-
ferrin and folic acid conjugates have been employed to aid ON
delivery to rapidly growing cells such as HL-60 cells (10, 11). In
the lung, alveolar macrophages (AMs) represent a major target
for dust-induced pulmonary fibrosis. These cells are also major
sources of TNFa production in the lung. The AMs possess
mannose-specific membrane receptors that can recognize and
internalize glycoproteins bearing mannose residues (12, 13).
On this basis, mannosylated glycoproteins could potentially be
used to target and enhance ON uptake by the AMs. Targeted
delivery of several cytotoxic drugs and antiviral agents by
glycoproteins specific to macrophages has been demonstrated
previously (14, 15). Moreover, 6-phosphomannosylated glyco-
proteins have also been used to target antisense ONs to peri-
toneal macrophages (16). In this study, we utilized mannosy-
lated polylysine (MPL) as a drug-targeting vector to aid the
cellular delivery of ONs to the AMs. The effectiveness of this
system in promoting antisense activity and its mechanism of
enhancement were evaluated.
EXPERIMENTAL PROCEDURES
Oligonucleotide Synthesis—Nuclease-resistant phosphorothioate ON
with a sequence complementary to the initiation codon of TNFa mRNA
(17) (59-TGTGCTCATGGTGTCTTT-39, AS-ON), its inverted sequence
(59-TTTCTGTGGTACTCGTGT-39, INV-ON), and sense sequence (59-
AAAGACACCATGAGCACA-39, S-ON) were synthesized on an auto-
mated solid phase synthesizer using standard phosphoramidite chem-
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istry (OligoTherapeutics Inc., Wilsonville, OR). A fluorescent label was
sometimes attached to the terminal 59 linkage group by the use of
59-carboxyfluorescein phosphoramidite. The ONs were purified by high
performance liquid chromatography and were .98% pure.
Synthesis of Mannosylated Polylysine—The MPL was synthesized
according to the method previously described (18). Briefly, poly-L-lysine
(Sigma, 0.25 mmol,Mr ' 10,000) was dissolved in 0.15 M NaCl solution.
The pH of the solution was adjusted to 9.0 using 0.1 N NaOH. 4-Iso-
thiocyanatophenyl-a-D-mannoside (Sigma, 12.5 mmol) was added in
small portions to the magnetically stirred protein solution. After a 6-h
reaction, the resulting solution was refrigerated overnight, and on the
following day the pH was adjusted to 7.0. Unreacted mannoside and
polylysine were removed by centrifugal filtration through a dialysis
membrane filter (DuraporeTM CL3K, Millipore Corp.) at 5000 3 g for 30
min. The degree of sugar substitution was determined by the resorcinol
sulfuric assay (19). The percentage of sugar in MPL was determined
using the equation X% 5 n 3 Mo/(Mp 1 n 3 M), where n is the number
of mannose residues per polylysine molecule andMo,Mp, andM are the
molecular weights of mannose, polylysine, and isothiocyanatophenyl-
mannoside, respectively. The MPL prepared under this condition was
found to contain '25% sugar.
Oligonucleotide-mannosylated Polylysine Complex—In a typical ex-
periment, the complex was prepared by adding 25 ml of 50 mg/ml MPL
to 25 ml of 50 mg/ml ON in culture medium for 1 h prior to use. In studies
designed to evaluate the dose effect of ON, various concentrations of ON
(25–100 mg/ml) were used. Complex formation was verified by gel elec-
trophoresis using a 6% polyacrylamide, 7 M urea gel. Using a dual
fluorescence labeling technique, we previously found that both the ON
and MPL, when prepared as a complex under this condition, were
co-internalized by the AMs (20). In a separate study, the stability of ON
and ONzMPL complex was studied in culture medium using gel elec-
trophoresis. After a 7-h incubation at 37 °C, no detectable degradative
products of ONs were observed.
Cell Preparations—The AMs were harvested from male Sprague-
Dawley rats (200–250 g) by bronchoalveolar lavage. Rats were anes-
thetized by intraperitoneal injection of sodium pentobarbital (0.2 g/kg of
body weight). The trachea was cannulated and the lungs lavaged 10
times with 8-ml aliquots of Ca21- and Mg21-free Hanks’ balanced salt
solution (145 mMNaCl, 5 mM KCl, 1.9 mMNaH2PO4, 5.5 mM glucose, pH
7.4). Lavaged cell suspensions were centrifuged at 500 3 g for 10 min at
4 °C. The cell pellets were washed twice by alternate resuspension and
centrifugation in macrophage-serum-free medium, pH 7.4 (Life Tech-
nologies, Inc.). Cell number and purity of the macrophage preparations
were determined using a Coulter electronic cell counter with a cell-
sizing attachment (Coulter Instrument, Hialeah, FL). The average val-
ues for yield and purity were 6.2 6 0.3 3 106 cells/rat and 92.5 6 0.4%,
respectively. Cell viability, measured via trypan blue exclusion, was
.95%. Aliquots of 0.1 ml containing 105 cells were added onto a 96-well
plate (Costar, Cambridge, MA) and incubated at 37 °C in a humidified
atmosphere at 5% CO2.
In studies involving the use of alveolar epithelial cells, the lungs
were lavaged as described above. They were then excised and incubated
for 20 min at 37 °C with phosphate-buffered saline containing elastase
(40 units/ml, Type I, U. S. Biochemical Corp.) and DNase (0.006%,
Sigma). After enzymatic digestion, the lungs were finely minced and the
digestion was arrested by incubation for 5 min in phosphate-buffered
saline containing 25% fetal bovine serum and 0.006% DNase (to help
prevent cell clumping). The crude extract was sequentially filtered
through 160- and 45-mm screens and centrifuged, and the resulting cell
pellet was spun on a sterile Percoll density gradient. The second cell
band from the surface was collected, washed twice, and resuspended in
Dulbecco’s modified Eagle’s medium. The cell suspension yielded 15–
20 3 106 cells/rat with viability greater than 95% as determined by the
Coulter counter and trypan blue exclusion.
Cell Culture—J774.1 cells, a macrophage cell line deficient in man-
nose receptors (21), were cultured in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% fetal bovine serum, 100 units/ml penicil-
lin, and 0.1 mg/ml streptomycin. They were maintained at 37 °C in a
humidified atmosphere containing 5% CO2. Prior to use, the cells were
washed and resuspended in macrophage-serum-free medium culture
medium.
Silica Exposure and Antisense Inhibition Studies—Cells were plated
on a 96-well plate at the density of 105 cells/well. They were treated
with heat-sterilized silica (Mil-U-Sil, endotoxin-free, Pennsylvania
Glass and Sand Corp.) or titanium dioxide (a nonfibrogenic dust control)
(Fisher), both at final concentrations of 10–100 mg/ml. To test the effect
of ONs on TNFa expression, the cells were simultaneously treated with
free oligomers (AS-ON, INV-ON, or S-ON) (25 mg/ml) or oligomers
complexed with MPL (ONzMPL, 25:25 mg/ml). After a 7-h incubation at
37 °C, the culture medium was collected and analyzed for TNFa using
a Genzyme TNFa enzyme-linked immunoadsorbent assay kit (Gen-
zyme Corp., Cambridge, MA) according to the manufacturer’s instruc-
tions. This assay is specific for TNFa and does not cross-react with
other cytokines, as stated by the manufacturer.
Analysis of TNFa mRNA was also performed using RT-PCR assay.
Total RNA was extracted from cells following treatments. Lysis buffer
(500 ml) containing 0.15 M NaCl, 10 mM Tris, pH 7.5, 1.5 mM MgCl2,
0.65% Nonidet P-40 was added to a cell pellet containing approximately
106 cells. The mixture was incubated for 5 min at 4 °C. After centrifu-
gation, the supernatant was mixed with an equal volume of urea-SDS
buffer (7 M urea, 10 mM Tris, pH 7.5, 10 mM EDTA, 1% SDS). Then
protein precipitation was carried out in the presence of 2 M NaCl. The
tubes were centrifuged and RNA was precipitated from the supernatant
with 2 volumes of ethanol. Reverse transcription and PCR (2 mg of RNA)
were performed using a Clontech RT-PCR kit according to the manu-
facturer’s instructions (Clontech Laboratories). Reactions were per-
formed on a Perkin-Elmer thermal cycler (model 480). As an internal
standard, b-actin cDNA was also amplified. Samples were denatured
for 2 min at 94 °C and then amplified for 25 cycles, with each cycle
consisting of three heated segments: 94 °C for 30 s, 55 °C for 30 s, and
74 °C for 90 s. Samples were held for a further 10 min at 74 °C on the
final cycle. The primers used were based on those previously reported
(22). Reaction products were precipitated and separated on a 7% poly-
acrylamide gel and visualized by ethidium bromide staining.
Cellular Uptake Studies—Cellular uptake studies were conducted
using fluorescently labeled AS-ON. The cells (105/well) were plated on a
96-well plate and incubated for 4 h at 37 °C in culture medium contain-
ing AS-ON (25 mg/ml) or AS-ONzMPL complex (25:25 mg/ml). The cells
were washed with cold medium containing excess unlabeled ON and/or
MPL to remove surface-bound labeled ON. The cells were then meas-
ured for their fluorescence intensity using a fluorescence microplate
reader at the excitation and emission wavelengths of 490 and 520 nm,
respectively. For competitive inhibition studies, cells were treated with
the AS-ONzMPL complex in the presence of 1 mg/ml mannosylated BSA
(a specific competitor for mannose receptors) (Sigma) or BSA (a non-
specific competitor).
Cell Viability—Cell viability was determined using fluorescence pro-
pidium iodide assay. After specific treatments the cells were incubated
with 1 mg/ml propidium iodide in culture medium for 10 min at 37 °C.
Cellular fluorescence intensity was then measured at the excitation and
emission wavelengths of 490 and 600 nm, respectively. Cell survival
was calculated as percentage cell survival 5 100 2 percentage cell
death.
Percentage cell death 5
measured signal 2 minimum signal
maximum signal 2 minimum signal
3 100%
The maximum signal is the fluorescence signal obtained in the presence
of Triton X-100 (0.1%), which was used to permeabilize the cells. The
minimum signal is the background autofluorescence signal.
Statistical Analysis—Data were analyzed by analysis of variance
with the use of the Newman-Keuls test for multiple comparisons. Sta-
tistical significance was considered at p , 0.05.
RESULTS
Stimulation of TNFa by Silica and Its Inhibition by Anti-
sense Oligonucleotides—Exposure of the AMs to crystalline
silica (10–100 mg/ml) resulted in a dose-dependent increase in
TNFa secretion over nontreated controls (Fig. 1). Treatment of
the cells with nonfibrogenic dust titanium dioxide at similar
concentrations had no significant effect on TNFa secretion (Fig.
1). In order to assess the potential inhibitory effect of antisense
ONs on silica-stimulated TNFa release, AS-ON (25 mg/ml) or
AS-ONzMPL complex (25:25 mg/ml) was added to the cells si-
multaneously with silica (100 mg/ml). As controls, noncomple-
mentary ON sequences (INV-ON and S-ON) and their respec-
tive MPL complexes (INV-ONzMPL and S-ONzMPL) at the
same concentrations were also used. Our results, shown in Fig.
2, indicated that treatment of the cells with free AS-ON had no
significant effect on TNFa level (p , 0.05). However, when the
AS-ON was given as a complex (AS-ONzMPL), .90% of the
TNFa secretion was inhibited. Non-antisense ONs, given ei-
ther alone or in the form of complexes, had no effect on TNFa
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level (p , 0.05). The latter results suggested that the inhibitory
effect of AS-ONzMPL complex was not due to MPL and that the
presence of AS-ONwas required for the anti-TNFa effect. Stud-
ies using MPL alone (see below) further confirmed this point.
The ability of AS-ONzMPL complex to suppress TNFa pro-
duction at the cellular level leads to the question of its molec-
ular mechanism of TNFa inhibition. To address this query,
AS-ONzMPL complex (25:25 mg/ml) was added to the AMs in
the presence of silica (100 mg/ml), and 4 h later mRNA for
TNFa was recovered and assessed by RT-PCR analysis. As
controls, AS-ON (25 mg/ml), INV-ON (25 mg/ml), or MPL (25
mg/ml) alone were also tested (Fig. 3). The addition of AS-
ONzMPL complex reduced the expression of silica-induced
TNFa mRNA, whereas all other control treatments had no
effect. These results are consistent with the earlier enzyme-
linked immunoadsorbent assay studies and suggest that the
mechanism of TNFa inhibition by the AS-ON complex is due to
translational inhibition of TNFa mRNA.
The lack of the inhibitory effect of free AS-ON is somewhat
surprising but may be attributed to its poor cellular uptake and
the inability to reach its intracellular target. Because previous
studies have established that cellular uptake of ONs is dose-
dependent (6), we therefore investigated the effect of ON con-
centration (25–100 mg/ml) on silica-induced TNFa production
(Fig. 4). Our result showed that an increase in ON concentra-
tion (AS-ON), as expected, resulted in a corresponding increase
in TNFa inhibition. A significant inhibitory effect ('35%) was
observed at the AS-ON concentration of 75 mg/ml (p , 0.05). At
the highest concentration tested (100 mg/ml), '50% inhibition
was observed. The control INV-ON had no significant effect on
TNFa production at all concentrations tested except at 100
mg/ml, at which concentration a minimal but significant effect
was observed ('15%) (p , 0.05). This latter result suggested
the possible nonsequence-specific effect of ON, which has been
reported in other systems when high concentrations of ONs are
used (23, 24). The potential cytotoxic effect of ONs at high
concentrations was also examined using fluorescence pro-
pidium iodide assay. The percentage of cells viable after treat-
ment with 100 mg/ml AS-ON was 94 6 5 and 92 6 4% for
INV-ON. These values were not significantly different from
that of the nontreated control (95 6 4%) (p , 0.05, n 5 4).
Antisense Oligonucleotide Cellular Uptake Mediated by Man-
nosylated Polylysine—To further examine the promoting effect
of MPL on antisense activity of AS-ON, cellular uptake studies
were conducted. In these studies, 59 fluorescently labeled
AS-ON was used to allow direct detection of cellular uptake.
AS-ON (25 mg/ml) or AS-ONzMPL complex (25:25 mg/ml) was
added to the AMs, and after indicated time intervals the cells
were washed and analyzed for their fluorescence intensity. As
shown in Fig. 5, the MPL greatly promoted the cellular uptake
of AS-ON. At 4 h of incubation, the uptake of the complex was
found to be '17-fold greater than that of the free AS-ON. This
result indicated that the MPL carrier system was highly effec-
tive at promoting the cellular uptake of AS-ON and that the
AS-ON alone was poorly taken up by the AMs. The saturable
nature of the complex uptake is indicative of receptor-mediated
endocytosis.
To test whether the cellular uptake of the MPL complex
occurred via mannose receptor-mediated endocytosis, cellular
uptake of the AS-ONzMPL complex in the presence of compe-
tition for mannose receptors was carried out. In these experi-
ments, the AS-ONzMPL complex was incubated with the AMs
in the presence of an excess amount of a specific mannose
receptor competitor, mannosylated BSA, or a nonspecific com-
petitor, BSA (Fig. 6). These results demonstrated that the
FIG. 1. Release of TNFa by alveolar macrophages after expo-
sure to silica or titanium dioxide. AMs (105/well) were incubated
with heat-sterilized silica or titanium dioxide (10–100 mg/ml) for 7 h in
culture medium at 37 °C in 5% CO2. After incubation, the culture
medium was collected and analyzed for TNFa. The data represent
mean 6 S.E. of four measurements obtained from different cell prepa-
rations. Asterisks denote a significant difference from untreated and
titanium-treated controls (p , 0.05).
FIG. 2. Antisense activity of ON mediated by MPL. Cells (105/
well) were incubated with silica (100 mg/ml) in the presence or absence
(Control) of free ON (25 mg/ml) or ONzMPL complex (25:25 mg/ml). After
a 7-h incubation at 37 °C, the culture samples were collected and
analyzed for TNFa. The values represent mean 6 S.E., n 5 4. Asterisk
indicates significant difference from control (p , 0.05).
FIG. 3. TNFa and b-actin mRNA expression in silica-exposed
AMs. Representative ethidium bromide-stained gels showing TNFa
and b-actin products (n 5 3) amplified from RNA of silica-treated AMs.
The cells were treated with silica (100 mg/ml) for 4 h at 37 °C in the
absence (A) or presence of AS-ONzMPL (25:25 mg/ml) (B), MPL (25
mg/ml) (C), AS-ON (25 mg/ml) (D), INV-ON (25 mg/ml) (E), and S-ON (25
mg/ml) (F). Total RNA was extracted and reversed transcribed, and the
resulting cDNA was amplified and electrophoresed as described under
“Experimental Procedures.”
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cellular uptake of the AS-ONzMPL complex was inhibited by
mannosylated BSA but not by BSA, thus indicating that the
ON uptake mediated by MPL occurred via the mannose recep-
tor pathway.
To further confirm the mechanism of AS-ON complex uptake
and to test the potential targeting ability of the MPL system,
uptake studies were repeated in the J774.1 macrophage cell
line, which is known to express a low level of mannose recep-
tors (21), and in alveolar epithelial cells, which lack mannose
receptors (Fig. 6). Both cell types exhibited a much lower com-
plex uptake compared with the AMs (p , 0.05), thus confirming
the mannose receptor-mediated complex uptake and the tar-
geting ability of the MPL carrier system.
DISCUSSION
Pulmonary macrophages are known to be sources of inflam-
matory mediators and fibrogenic factors and are one of the first
cells to respond to inhaled particles in the lung. Several studies
have shown that TNFa plays an important role in the patho-
genesis of silicotic fibrosis. Driscoll et al. (1) demonstrated an
increase in TNFa production by the AMs in rats treated with
silica. Piguet et al. (2) later showed that this increase in TNFa
production was associated with increased expression of TNFa
mRNA in the lung, although the cellular origin of TNFa was
not identified in this study. The work by Piguet et al. (2) also
demonstrated that pretreatment of the animals with anti-
TNFa IgG or exogenous recombinant TNFa reduced and aug-
mented, respectively, silica-induced fibrosis. Thus, these stud-
ies strongly indicate the role of TNFa in silicotic fibrosis.
There are, however, a number of studies that have reported
contradictory results. Mohr et al. (25) and Lemaire (26) showed
that silica treatment in rats had no effect on TNFa production
by the AMs. Bissonnette and Rola-Pleszczynski (27) similarly
reported the lack of silica effect in mice. The discrepancies
between test results by different groups may be attributed to
differences in experimental conditions, i.e. the dose and type of
silica used and the mode of silica instillation. With regard to
the dose, Driscoll et al. (1) showed that silica stimulation of
TNFa release occurred only at doses greater than 50 mg/kg.
Lemaire (26) also reported the lack of silica effect on TNFa
release at a low silica dose of 15 mg/kg. In agreement with
these in vivo data, our in vitro results indicated a dose-depend-
ent effect of silica on TNFa production by the AMs. Silica
directly stimulated TNFa secretion and mRNA expression, ef-
fects that were not observed with the nonfibrogenic dust tita-
nium dioxide. These results confirm and extend those of Gosset
et al. (28) and Driscoll et al. (29), who reported a direct effect of
silica on TNFa production in isolated human and rat AMs, and
those of Savici et al. (30), who reported an elevated TNFa gene
FIG. 4. Effect of free ON concentration on silica-induced TNFa
release. Cells (105/well) were incubated with silica (100 mg/ml) in the
presence of varying amounts of free ONs (25–100 mg/ml) in culture
medium. After a 7-h incubation at 37 °C, the culture samples were
collected and analyzed for TNFa. The values represent mean 6 S.E.,
n 5 4. Asterisks indicate significant differences from non-ON-treated
control (p , 0.05).
FIG. 5. Comparison of cellular uptake of free ON or ON com-
plexed with MPL. Cells (105/well) were incubated with free AS-ON
(25 mg/ml) or AS-ONzMPL complex (25:25 mg/ml) for 4 h in culture
medium at 37 °C in 5% CO2. After incubation, the cells were washed
with fresh medium containing excess unlabeled ON and/or MPL to
remove surface-bound labeled ON. The cells were then measured for
their fluorescence intensity using a fluorescence microplate reader at
the excitation and emission wavelengths of 490 and 520 nm, respec-
tively. The values represent mean 6 S.E., n 5 4.
FIG. 6. Mechanism of ON uptake mediated by MPL. AMs (105
cells/well) were incubated with AS-ONzMPL complex (25:25 mg/ml) at
37 °C for 4 h in the absence (A) or presence of mannosylated albumin (B,
1 mg/ml) as a specific competitor for mannose receptor or albumin (C, 1
mg/ml) as a nonspecific competitor. Experiments were also conducted
using J774.1 (D) or alveolar epithelial cells (E) (both at 105/well) in the
presence of AS-ONzMPL (25:25 mg/ml). Cellular uptake was monitored
fluorometrically as described in Fig. 5. The values represent mean 6
S.E., n 5 4. Asterisks indicate significant differences from control (A)
(p , 0.05).
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expression in THP-1 myelomonocytic cells following silica
treatment.
The regulatory role of TNFa in fibrogenesis and its potential
therapeutic intervention can be studied at the molecular level
using antisense ONs. These compounds have the potential to
interfere selectively with cellular protein synthesis by se-
quence-specific hybridization to DNA or RNA molecules. Since
the gene sequence encoding TNFa had been previously identi-
fied (17), we predicted that specific antisense sequences could
be synthesized and used to inhibit TNFa expression and there-
fore fibrosis. To investigate this possibility, we utilized an
antisense ON specific to the initiation codon of the TNFa
mRNA (AS-ON) and tested its effect on the macrophage cyto-
kine gene expression. Our results indicate that AS-ON can be
used to inhibit TNFa expression. However, when used alone
this compound is relatively ineffective, and high concentrations
are required to elicit the effect. At a high concentration of 100
mg/ml, AS-ON causes #50% inhibition of TNFa production.
Because high concentrations of ONs are commonly associated
with nonsequence-specific effects (23, 24), innovative ap-
proaches to improving potency of ONs are desirable.
It has been reported that ONs, due to their polyanionic
nature, poorly permeate cell membranes to reach their intra-
cellular targets (31, 32). Several research groups (23, 33, 34)
also observed that in the absence of appropriate delivery sys-
tems ONs exhibited no antisense activity, whereas in the pres-
ence of these delivery systems, i.e. liposomes, ONs showed
strong activity. These observations suggest that ONs do not
normally enter the cells to a significant extent, and therefore
approaches to improve their cellular uptake are important for
their effective use. In agreement with previous findings, our
results indicated that the cellular uptake of free ON by the
AMs is very low, and this may account for the observed low
activity of the AS-ON. This conclusion is supported by a dra-
matic and parallel increase in cellular uptake and anti-TNFa
activity of the AS-ON when given as a complex with the MPL.
At a low concentration of AS-ON (25 mg/ml), the MPL (25
mg/ml) promoted a 17-fold increase in cellular uptake of the ON
and caused $90% TNFa inhibition. At this concentration level,
the AS-ON alone had no significant effect on TNFa. The effect
of AS-ONzMPL complex on TNFa activity was associated with
specific ablation of targeted mRNA as shown by RT-PCR. Con-
trol studies also showed that the promoting effect of MPL was
not associated with loss of cell viability as determined by fluo-
rescence propidium iodide assay. Furthermore, MPL alone or
complexed with non-antisense ONs (INV-ON and S-ON) had no
effect on TNFa activity. Thus, these results suggested that the
promoting effect of MPL was most likely due to enhanced ON
uptake.
To further confirm these observations and to test the mech-
anism of ON uptake mediated by the MPL, a series of cellular
uptake experiments was conducted. Our results indicated that
MPL promoted the cellular uptake of AS-ON via mannose
receptor-mediated pathway since competition for mannose re-
ceptors by mannosylated BSA inhibited the uptake of the AS-
ONzMPL complex and the noncompetitor BSA had no effect.
Furthermore, cells lacking mannose receptors (epithelial cells)
or bearing few receptors (J774.1 cells) did not appreciably take
up the AS-ONzMPL complex. The latter results also indicated
the potential targeting ability of the MPL carrier system for the
AMs.
In conclusion, we have demonstrated that antisense ON tar-
geted to the TNFa mRNA can be used to inhibit TNFa expres-
sion in AMs. The findings in this study have a direct implica-
tion on the therapeutic utilization of ONs in pulmonary
fibrosis. A similar strategy may be employed to aid the study of
specific cytokine functions and their role in disease pathogen-
esis. Effective utilization of antisense ONs requires develop-
ment of appropriate delivery systems capable of effective and
selective transfer of ONs to the target cells. With regard to the
AMs, we have shown that the MPL delivery system is effective
and selective in promoting the cellular delivery and antisense
activity of ON. The system exploits the efficient receptor-me-
diated endocytosis to achieve cell-specific antisense delivery.
Because the system utilizes a naturally occurring cellular proc-
ess, it is potentially nontoxic. Although our in vitro studies
indicate the relative safety of this system, further in vivo stud-
ies are needed. Demonstration of its safety and efficacy will
allow further development of this system for therapeutic
purposes.
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